Iambic Therapeutics Stock

www.iambic.aiHealthcare / Healthcare softwareFounded: 2019Funding to Date: $333.01MM

Iambic Therapeutics, based in San Diego, redefines drug discovery by combining human ingenuity with the power of AI. Emphasizing AI-driven design and automation, the company is a pioneer in creating data-efficient, physics-informed AI models. Iambic Therapeutics achieves more reliable and accurate modeling by incorporating physics principles into AI architectures, enabling deeper exploration in chemical space and accelerating the journey toward innovative medical solutions.

Register To Buy and Sell Shares

For more details on financing and valuation for Iambic Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Iambic Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Iambic Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Thomas Miller Ph.D
Co-Founder & Chief Executive Officer
Fred Manby Ph.D
Co-Founder & Chief Technology Officer
Chao Zhang Ph.D
Chief Scientific Officer

Board Members

Aaron Weiner
Coatue Management
Jishnu Bhattacharjee
Nexus Venture Partners
R. Jacob Vogelstein Ph.D
Catalio Capital Management

Iambic Therapeutics’ stock FAQs

plusminus

Can you buy Iambic Therapeutics’ stock?

Iambic Therapeutics is not publicly traded on NYSE or NASDAQ in the U.S. To buy Iambic Therapeutics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus

Can you sell Iambic Therapeutics’ stock?

Yes, you can sell stock of a private company like Iambic Therapeutics. Forge can help you sell your Iambic Therapeutics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus

What is Iambic Therapeutics’ stock price?

Iambic Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Iambic Therapeutics’ private market stock price with Forge Data.
plusminus

What is Iambic Therapeutics’ stock ticker symbol?

Iambic Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Iambic ups rhythm in AI-enabled race to clinic, revealing $100M round and Nvidia pact

Iambic Therapeutics is finding its rhythm, raising $100 million and partnering with the shovel seller of the artificial intelligence gold rush to advance a pipeline led by a pair of cancer candidates into the clinic. The San Diego-based biotech is built on technologies for predicting protein-ligand structures, generating molecular designs and other drug discovery tasks.
Updated on: Jun 18, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.